Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance

Author's Avatar
Mar 31, 2022

Biocept%2C+Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December 31, 2021 of approximately $28 million.